Showing results (1-10 of 209) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Sunitinib: from rational design to clinical efficacyLaura Q M Chow, S Gail Eckhardt
Cancer Chemotherapy and Pharmacology|December 7, 2007
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsLaura Q M Chow, S Gail Eckhardt, Cindy L O'Bryant, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancerLaura Q M Chow
Frontiers in Oncology|July 30, 2016
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsNatalie J Serkova, S Gail Eckhardt
The Oncologist|June 13, 2015
The Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentGregory K Pennock, Laura Q M Chow
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)Avi Ashkenazi, Pamela Holland, S Gail Eckhardt
Nature Reviews. Clinical Oncology|November 11, 2015
The changing landscape of phase I trials in oncologyKit Man Wong, Anna Capasso, S Gail Eckhardt
Expert Opinion on Investigational Drugs|April 13, 2012
JAK2 inhibition for the treatment of hematologic and solid malignanciesBrian L Harry, S Gail Eckhardt, Antonio Jimeno
JAMA Oncology|November 5, 2016
Harnessing the Immune System as a Therapeutic Tool in Virus-Associated CancersRafael Santana-Davila, Shailender Bhatia, Laura Q M Chow
Cancer Chemotherapy and Pharmacology|March 6, 2008
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignanciesLaura Q M Chow, Daniel L Gustafson, Cindy L O'Bryant, et al.
Pageof 21